JP2000510098A5 - - Google Patents

Download PDF

Info

Publication number
JP2000510098A5
JP2000510098A5 JP1997532954A JP53295497A JP2000510098A5 JP 2000510098 A5 JP2000510098 A5 JP 2000510098A5 JP 1997532954 A JP1997532954 A JP 1997532954A JP 53295497 A JP53295497 A JP 53295497A JP 2000510098 A5 JP2000510098 A5 JP 2000510098A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP1997532954A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000510098A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/004462 external-priority patent/WO1997036860A1/en
Publication of JP2000510098A publication Critical patent/JP2000510098A/ja
Publication of JP2000510098A5 publication Critical patent/JP2000510098A5/ja
Abandoned legal-status Critical Current

Links

JP09532954A 1996-03-29 1997-03-25 桂皮酸誘導体 Abandoned JP2000510098A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1432596P 1996-03-29 1996-03-29
US60/014,325 1996-03-29
PCT/US1997/004462 WO1997036860A1 (en) 1996-03-29 1997-03-25 Cinnamic acid derivatives and their use as integrin antagonists

Publications (2)

Publication Number Publication Date
JP2000510098A JP2000510098A (ja) 2000-08-08
JP2000510098A5 true JP2000510098A5 (cg-RX-API-DMAC10.html) 2004-12-02

Family

ID=21764797

Family Applications (1)

Application Number Title Priority Date Filing Date
JP09532954A Abandoned JP2000510098A (ja) 1996-03-29 1997-03-25 桂皮酸誘導体

Country Status (11)

Country Link
US (1) US5852210A (cg-RX-API-DMAC10.html)
EP (1) EP0894084B1 (cg-RX-API-DMAC10.html)
JP (1) JP2000510098A (cg-RX-API-DMAC10.html)
AT (1) ATE219764T1 (cg-RX-API-DMAC10.html)
AU (1) AU2337197A (cg-RX-API-DMAC10.html)
CA (1) CA2250690A1 (cg-RX-API-DMAC10.html)
DE (1) DE69713582T2 (cg-RX-API-DMAC10.html)
DK (1) DK0894084T3 (cg-RX-API-DMAC10.html)
ES (1) ES2179318T3 (cg-RX-API-DMAC10.html)
PT (1) PT894084E (cg-RX-API-DMAC10.html)
WO (1) WO1997036860A1 (cg-RX-API-DMAC10.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW460460B (en) * 1997-11-04 2001-10-21 Chugai Pharmaceutical Co Ltd Heterocyclic compounds having NOS inhibitory activities
CA2327673C (en) 1998-04-09 2009-08-25 Meiji Seika Kaisha, Ltd. Aminopiperidine derivatives as integrin .alpha.v.beta.3 antagonists
US6329547B1 (en) 1998-05-25 2001-12-11 Santen Pharmaceutical Co., Ltd. Vinylbenzene derivatives
GB9818641D0 (en) * 1998-08-26 1998-10-21 Rh Ne Poulenc Rorer Limited Chemical compounds
US6677360B2 (en) * 1998-12-16 2004-01-13 Bayer Aktiengesellschaft Biphenyl and biphenyl-analogous compounds as integrin antagonists
US6420396B1 (en) 1998-12-16 2002-07-16 Beiersdorf Ag Biphenyl and biphenyl-analogous compounds as integrin antagonists
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
WO2000038719A1 (en) 1998-12-23 2000-07-06 G.D. Searle & Co. Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
US6291503B1 (en) 1999-01-15 2001-09-18 Bayer Aktiengesellschaft β-phenylalanine derivatives as integrin antagonists
AU6315300A (en) * 1999-07-26 2001-02-13 Shionogi & Co., Ltd. Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same
WO2001010844A1 (fr) 1999-08-05 2001-02-15 Meiji Seika Kaisha, Ltd. DERIVES D'ACIDE φ-AMINO-α-HYDROXYCARBOXYLIQUE POSSEDANT UN ANTAGONISME αvβ3 D'INTEGRINE
US20050059669A1 (en) * 1999-10-08 2005-03-17 Keiichi Ajito M-substituted benzoic acid derivatives having integrin alpha v beta 3 antagonistic activity
EP1250935A1 (en) * 2000-01-25 2002-10-23 Meiji Seika Kaisha Ltd. REMEDIES FOR REPERFUSION INJURY CONTAINING INTEGRIN ALPHAvBETA3 ANTAGONIST
RU2240826C2 (ru) 2000-02-03 2004-11-27 Эйсай Ко., Лтд. Ингибитор экспрессии интегрина
WO2001096334A2 (en) * 2000-06-15 2001-12-20 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
US6900232B2 (en) 2000-06-15 2005-05-31 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists
US20040043988A1 (en) * 2001-06-15 2004-03-04 Khanna Ish Kurmar Cycloalkyl alkanoic acids as intergrin receptor antagonists
EP2428226A1 (en) 2001-10-22 2012-03-14 The Scripps Research Institute Antibody targeting compounds
AU2003213682C1 (en) * 2002-03-04 2008-06-12 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin alphavbeta3 antagonist in combination with an HMG-CoA reductase inhibitor or a bisphosphonate
CA2478239A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
BR0316875A (pt) * 2002-12-20 2005-10-25 Pharmacia Corp Compostos de pirazol como derivados antagonistas receptores da integrina, sua composição farmacêutica e respectivo uso
EP1592421A1 (en) * 2002-12-20 2005-11-09 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
EP1572690A1 (en) * 2002-12-20 2005-09-14 Pharmacia Corporation Thiazole compounds as integrin receptor antagonists derivatives
EP1596884A2 (en) * 2003-01-30 2005-11-23 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
TWI396543B (zh) 2005-05-12 2013-05-21 Sankyo Co 取代丙烯醯胺衍生物及含有它之醫藥組成物
CA2630415A1 (en) * 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
WO2008053861A1 (en) * 2006-10-30 2008-05-08 Santen Pharmaceutical Co., Ltd. Novel compound having 1,4-benzoxazin-3-one skeleton
WO2008053863A1 (en) * 2006-10-30 2008-05-08 Santen Pharmaceutical Co., Ltd. Novel compound having 1,4-benzothiazin-3-one skeleton or 3,4-dihydroquinolin-2-one skeleton
PL2222636T3 (pl) 2007-12-21 2014-04-30 Ligand Pharm Inc Selektywne modulatory receptorów androgenowych (SARM) i ich zastosowania
WO2010093706A2 (en) 2009-02-10 2010-08-19 The Scripps Research Institute Chemically programmed vaccination
CN104640857B (zh) 2012-07-18 2017-07-04 圣路易斯大学 作为整合素拮抗剂的β氨基酸衍生物
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
MX2016015467A (es) 2014-05-30 2017-03-23 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos.
CN105272888B (zh) * 2014-06-24 2018-03-27 中国科学院上海药物研究所 双芳基烯烷酸类化合物及其制备方法和用途
ES2806276T3 (es) 2015-12-30 2021-02-17 Univ Saint Louis Derivados de ácido aminobenzoico meta-azaciclicos como antagonistas pan-integrina
AU2020257397A1 (en) 2019-04-19 2021-12-16 Ligand Pharmaceuticals Inc. Crystalline forms and methods of producing crystalline forms of a compound
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5039805A (en) * 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
WO1993008823A1 (en) * 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
AU3141693A (en) * 1991-11-22 1993-06-15 Friedman, Mark M. Non-peptidic surrogates of the arg-gly-asp sequence and pharmaceutical compositions comprising them
US5523302A (en) * 1993-11-24 1996-06-04 The Du Pont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
JPH10501222A (ja) * 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them

Similar Documents

Publication Publication Date Title
JP2000502280A5 (cg-RX-API-DMAC10.html)
JP2000501771A5 (cg-RX-API-DMAC10.html)
JP2000501599A5 (cg-RX-API-DMAC10.html)
JP2001509188A5 (cg-RX-API-DMAC10.html)
JP2000516913A5 (cg-RX-API-DMAC10.html)
JP2000507420A5 (cg-RX-API-DMAC10.html)
JP2000502472A5 (cg-RX-API-DMAC10.html)
JP2000501825A5 (cg-RX-API-DMAC10.html)
JP2000501338A5 (cg-RX-API-DMAC10.html)
JP2000500874A5 (cg-RX-API-DMAC10.html)
JP2001500768A5 (cg-RX-API-DMAC10.html)
JP2000502425A5 (cg-RX-API-DMAC10.html)
JP2000502485A5 (cg-RX-API-DMAC10.html)
JP2000501774A5 (cg-RX-API-DMAC10.html)
JP2000500912A5 (cg-RX-API-DMAC10.html)
JP2000502570A5 (cg-RX-API-DMAC10.html)
JP2000501876A5 (cg-RX-API-DMAC10.html)
JP2000510098A5 (cg-RX-API-DMAC10.html)
JP2000501744A5 (cg-RX-API-DMAC10.html)
JP2000501229A5 (cg-RX-API-DMAC10.html)
JP2000500857A5 (cg-RX-API-DMAC10.html)
JP2000502316A5 (cg-RX-API-DMAC10.html)
JP2000502714A5 (cg-RX-API-DMAC10.html)
JP2000501569A5 (cg-RX-API-DMAC10.html)
JP2000500318A5 (cg-RX-API-DMAC10.html)